Kalaris Therapeutics, Inc. (KLRS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kalaris Therapeutics, Inc. (KLRS) has a cash flow conversion efficiency ratio of -0.195x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.35 Million) by net assets ($68.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Kalaris Therapeutics, Inc. worth for the company's overall valuation and market capitalisation.
Kalaris Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Kalaris Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kalaris Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kalaris Therapeutics, Inc. ranked by their cash flow conversion efficiency. See Kalaris Therapeutics, Inc. cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Media Prima Bhd
KLSE:4502
|
0.072x |
|
APEX International Financial Engineering Res & Tech Co Ltd
TWO:5210
|
0.016x |
|
Adrad Holdings Ltd
AU:AHL
|
0.050x |
|
Lifetime Brands Inc
NASDAQ:LCUT
|
-0.120x |
|
Escort Teknoloji Yatirim AS
IS:ESCOM
|
0.000x |
|
SMJ International Holdings Inc.
NYSE MKT:SMJF
|
N/A |
|
Alithya Group Inc
NASDAQ:ALYAF
|
-0.048x |
|
Northern Technologies
NASDAQ:NTIC
|
0.004x |
Annual Cash Flow Conversion Efficiency for Kalaris Therapeutics, Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Kalaris Therapeutics, Inc. from 2018 to 2025. View Kalaris Therapeutics, Inc. stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $78.81 Million | $-42.98 Million | -0.545x | +8.74% |
| 2024-12-31 | $113.31 Million | $-67.70 Million | -0.598x | -290.34% |
| 2023-12-31 | $-45.02 Million | $-14.13 Million | 0.314x | -2.82% |
| 2022-12-31 | $-30.27 Million | $-9.78 Million | 0.323x | +168.44% |
| 2021-12-31 | $225.27 Million | $-106.32 Million | -0.472x | -174.02% |
| 2020-12-31 | $353.06 Million | $-60.81 Million | -0.172x | -3.94% |
| 2019-12-31 | $121.62 Million | $-20.16 Million | -0.166x | -284.07% |
| 2018-12-31 | $21.58 Million | $1.94 Million | 0.090x | -- |
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudativ… Read more